Impact of Whole Abdomen Radiation Therapy Integrated in the Management of Recurrent Epithelial Ovarian Cancer

TANG Jie,CAI Shu-mo,HUANG Xiao,LI Zi-ting,ZANG Rong-yu

DOI: https://doi.org/10.3969/j.issn.1007-3639.2006.11.013

2006-01-01

Abstract:Background and purpose:As there is no agreed second-line treatment at relapse, patients with recurrent ovarian cancer often have a pessimistic outcome. Rational integrated therapy may improve the survival of patients in this setting. This prospective study was conducted to access the role of whole abdomen radiotherapy in recurrent patients. Methods:11 patients with recurrent epithelial ovarian cancer received second-line chemotherapy, either platinum-based or paclitaxal-based regimen. Secondary debukling surgery was indicated to patients with limited and intra-abdominopelvic lesions. Additional whole abdomen irradiation was performed, by means of hyperfractionated and split course radiation.Results:11 patients received mean 7 courses (5-11courses) second-line chemotherapy and all acquired complete response. Among 8 patients who underwent secondary debulking surgery, 7 cases acquired optimal cytoreduction (the largest residual tumor ≤1cm). After remission by the second-line chemotherapy, all patients received whole abdominal radiation. 7 patients completed the whole radiation therapy, with total dose of 30.2Gy(29.96-31.2Gy)to the abdomen and additional pelvic boost to 45.1Gy (44.98-45.12Gy) in 4 cases. With mean follow-up of 40.9 months, the 3 and 5-year overall survival rate were 90.91% and 81.82%, respectively. The median survival time was more than 60 months. The 3-year survival rate after recurrence was 72.73%. 10 women experienced tumor relapse again. Their median tumor-free survival was 22.0months, and 1-3 year tumor-free survival rate were 72.73%,45.45% and 18.18%, respectively. 1-3 year local tumor control rate for the abdominal-pelvic cavity were 72.7% (8/11),63.6% (7/11) and 54.5% (6/11) , respectively. During irradiation, bone-marrow suppression was seen in all patients, with both Grade 3 neutropenia and Grade 3 thrombocytopenia in 3 cases (27.3%). Acute gastrointestinal complication of radiotherapy was mild. Most patients had Grade Ⅰ/Ⅱ gastrointestinal toxicity. Late toxicity concluded one patients with prolonged thrombocytopenia (Grade Ⅲ) and 1 patients with small bowel obstruction.Conclusions:The results suggested that second-line chemotherapy combined with whole abdomen irradiation may increase the local tumor control rate of abdominopelvic cavity and postpone the following recurrence of tumor and prolong the overall survival of the patients with recurrent ovarian cancer. The acute toxicity of hyperfractionated and split course abdominopelvic irradiation was mild and well tolerated.